Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894 , September 2000

Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective

  • Daren K Heyland

      Affiliations

    • Department of Medicine, Queen's University, Kingston, Ontario, Canada
    • Corresponding Author InformationCorresponding author. Angada 3, Kingston General Hospital, Kingston, Ontario, Canada K7L 2V7. Tel: 613-549-6666x3339; fax: 613-548-2577.
    • ,
  • Amiram Gafni

      Affiliations

    • Center for Health Economics and Policy Analysis and Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
    • ,
  • Mitchell A.H Levine

      Affiliations

    • Center for Evaluation of Medicines, St. Joseph's Hospital, Hamilton, Ontario, Canada

Received 27 August 1998 ,Revised 16 July 1999 ,Accepted 28 October 1999.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Dr. Heyland is a Career Scientist with the Ministry of Health of Ontario. This Study not funded.

☆☆ Evaluation Study as of July 3, 1999.

PII: S0895-4356(99)00214-0

Journal of Clinical Epidemiology
Volume 53, Issue 9 , Pages 888-894 , September 2000

Article Tools

* Image Usage & Resolution